Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
NCT01640340
Completed
Palonosetron is different from ondansetron because it stays in the body longer and may prevent nausea and vomiting for a longer period of time than ondansetron. It is standard practice to use dexamethasone and aprepitant with either ondansetron or palonosetron to prevent nausea and vomiting caused by highly emetogenic chemotherapy. Although these combinations are commonly used, they have never been compared to each other. The purpose of this study is to record the amount of nausea and vomiting,... Read More
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
10/13/2013
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Malignant Neoplasm
Register for Updates
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
NCT00002812
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
08/23/2013
Locations: Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio +2 locations
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
NCT00002816
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
08/21/2013
Locations: Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio +2 locations
Conditions: Leukemia
Register for Updates
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
NCT00366106
Terminated
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2012
Locations: Tri-County Hematology and Oncology Associates, Canton, Ohio +1 locations
Conditions: Multiple Myeloma
Register for Updates
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: Mid Ohio Oncology & Hematology, Inc., Columbus, Ohio
Conditions: Multiple Myeloma
Register for Updates
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT00474188
Terminated
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2009
Locations: James Cancer Hospital, Columbus, Ohio
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates